No Data
No Data
Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer
Earnings Week Ahead: PepsiCo, Delta Air Lines, JPMorgan, Citigroup and More
Nurix Therapeutics(NRIX.US) Officer Sells US$119.84K in Common Stock
$Nurix Therapeutics(NRIX.US)$ Officer Ring Christine sold 5,760 shares of common stock on Jul 1, 2024 at an average price of $20.805 for a total value of $119.84K.Source: Announcement What is statemen
Form 144 | Nurix Therapeutics(NRIX.US) Officer Proposes to Sell 120.21K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Nurix Therapeutics(NRIX.US)$ Officer CHRISTINE RING intends to sell 5,760 shares of its common stock on Jul 1, with a total market value of approximately $120.21K. CH
Expert Outlook: Nurix Therapeutics Through The Eyes Of 14 Analysts
In the last three months, 14 analysts have published ratings on Nurix Therapeutics (NASDAQ:NRIX), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their rece
Nurix Therapeutics Is Maintained at Outperform by RBC Capital
Nurix Therapeutics Is Maintained at Outperform by RBC Capital